{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:42:43Z","timestamp":1781566963845,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jcyt.2019.10.005","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T21:15:36Z","timestamp":1576098936000},"page":"1198-1205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor\u2013T cell manufacture"],"prefix":"10.1016","volume":"21","author":[{"given":"Seshu","family":"Tyagarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Acker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Rutjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2019.10.005_bib0001","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2015-0421","article-title":"Chimeric antigen receptor T-cell therapy for the community oncologist","volume":"21","author":"Maus","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jcyt.2019.10.005_bib0002","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jcyt.2019.10.005_bib0003","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"9","key":"10.1016\/j.jcyt.2019.10.005_bib0004","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jcyt.2017.06.001","article-title":"Building blocks for institutional preparation of CTL019 delivery","volume":"19","author":"McGuirk","year":"2017","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2019.10.005_bib0005","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1097\/HS9.0000000000000018","article-title":"Chimeric antigen receptor-T cell therapy: practical considerations for implementation in Europe","volume":"2","author":"Buechner","year":"2018","journal-title":"HemaSphere"},{"issue":"95","key":"10.1016\/j.jcyt.2019.10.005_bib0006","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"303","key":"10.1016\/j.jcyt.2019.10.005_bib0007","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.jcyt.2019.10.005_bib0008","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcyt.2019.10.005_bib0009","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jcyt.2019.10.005_bib0010","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2019.10.005_bib0011","series-title":"Full Prescribing Information","year":"2018"},{"key":"10.1016\/j.jcyt.2019.10.005_bib0012","series-title":"Summary of Product Characteristics","year":"2018"},{"key":"10.1016\/j.jcyt.2019.10.005_bib0013","series-title":"Health Canada Product Monograph","year":"2018"},{"key":"10.1016\/j.jcyt.2019.10.005_bib0014","unstructured":"KymriahTM, Zellsuspension zur Infusion (Tisagenlecleucelum). https:\/\/www.swissmedic.ch\/swissmedic\/de\/home\/humanarzneimittel\/authorisations\/new-medicines\/kymriahtm_zellsuspensionzurinfusiontisagenlecleucelum.html. [accessed February 20, 2019]."},{"key":"10.1016\/j.jcyt.2019.10.005_bib0015","series-title":"Australian Prescribing Information","year":"2018"},{"issue":"8","key":"10.1016\/j.jcyt.2019.10.005_bib0016","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.jcyt.2019.10.005_bib0017","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.4049\/jimmunol.179.7.4910","article-title":"4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy","volume":"179","author":"Zhang","year":"2007","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jcyt.2019.10.005_bib0018","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.jcyt.2019.10.005_bib0019","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tmrv.2016.03.001","article-title":"CAR-T cell therapies from the transfusion medicine perspective","volume":"30","author":"Fesnak","year":"2016","journal-title":"Transfus Med Rev"},{"issue":"23","key":"10.1016\/j.jcyt.2019.10.005_bib0020","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1182\/blood.V126.23.3100.3100","article-title":"Successful translation of chimeric antigen receptor (CAR) targeting CD19 (CTL019) cell processing technology from academia to industry","volume":"126","author":"Boyd","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jcyt.2019.10.005_bib0021","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jcyt.2019.10.005_bib0022","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jcyt.2019.10.005_bib0023","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1128\/CVI.00342-08","article-title":"Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization","volume":"16","author":"Weinberg","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.jcyt.2019.10.005_bib0024","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cryobiol.2008.06.002","article-title":"T cell responses in fresh and cryopreserved peripheral blood mononuclear cells: kinetics of cell viability, cellular subsets, proliferation, and cytokine production","volume":"57","author":"Jeurink","year":"2008","journal-title":"Cryobiology"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2019.10.005_bib0025","article-title":"The post-thaw recovery of cryopreserved chimeric antigen receptor (CAR) T-cells during manufacture is better than that of cryopreserved peripheral blood CD3+ cells","volume":"130","author":"Elavia","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2019.10.005_bib0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/CJI.0000000000000199","article-title":"Preclinical optimization of a CD20-specific chimeric antigen receptor vector and culture conditions","volume":"41","author":"Lee","year":"2018","journal-title":"J Immunother"},{"issue":"6","key":"10.1016\/j.jcyt.2019.10.005_bib0027","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jcyt.2019.10.005_bib0028","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2019.10.005_bib0029","first-page":"1","article-title":"Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL","author":"Roberts","year":"2017","journal-title":"Leuk Lymphoma"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324919308667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324919308667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:40:05Z","timestamp":1761442805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324919308667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1465324919308667"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.10.005","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor\u2013T cell manufacture","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}